

**United States Bankruptcy Court
District of Massachusetts**

In re Inspiration Biopharmaceuticals, Inc.
Debtor

Case No. 12-18687

Chapter 11

SUMMARY OF SCHEDULES

Indicate as to each schedule whether that schedule is attached and state the number of pages in each. Report the totals from Schedules A, B, D, E, F, I, and J in the boxes provided. Add the amounts from Schedules A and B to determine the total amount of the debtor's assets. Add the amounts of all claims from Schedules D, E, and F to determine the total amount of the debtor's liabilities. Individual debtors must also complete the "Statistical Summary of Certain Liabilities and Related Data" if they file a case under chapter 7, 11, or 13.

NAME OF SCHEDULE	ATTACHED (YES/NO)	NO. OF SHEETS	ASSETS	LIABILITIES	OTHER
A - Real Property	Yes	1	0.00		
B - Personal Property	Yes	4	20,383,300.95		
C - Property Claimed as Exempt	Yes	1			
D - Creditors Holding Secured Claims	Yes	1		203,303,810.65	
E - Creditors Holding Unsecured Priority Claims (Total of Claims on Schedule E)	Yes	5		148,885.65	
F - Creditors Holding Unsecured Nonpriority Claims	Yes	35		37,597,163.38	
G - Executory Contracts and Unexpired Leases	Yes	1			
H - Codebtors	Yes	1			
I - Current Income of Individual Debtor(s)	No	0			N/A
J - Current Expenditures of Individual Debtor(s)	No	0			N/A
Total Number of Sheets of ALL Schedules		49			
		Total Assets	20,383,300.95		
		Total Liabilities		241,049,859.68	

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE A - REAL PROPERTY

Except as directed below, list all real property in which the debtor has any legal, equitable, or future interest, including all property owned as a cotenant, community property, or in which the debtor has a life estate. Include any property in which the debtor holds rights and powers exercisable for the debtor's own benefit. If the debtor is married, state whether husband, wife, both, or the marital community own the property by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community." If the debtor holds no interest in real property, write "None" under "Description and Location of Property."

Do not include interests in executory contracts and unexpired leases on this schedule. List them in Schedule G - Executory Contracts and Unexpired Leases.

If an entity claims to have a lien or hold a secured interest in any property, state the amount of the secured claim. See Schedule D. If no entity claims to hold a secured interest in the property, write "None" in the column labeled "Amount of Secured Claim." If the debtor is an individual or if a joint petition is filed, state the amount of any exemption claimed in the property only in Schedule C - Property Claimed as Exempt.

Description and Location of Property	Nature of Debtor's Interest in Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption	Amount of Secured Claim
--------------------------------------	---	------------------------------------	--	-------------------------

None

Sub-Total > 0.00 (Total of this page)

Total > 0.00

(Report also on Summary of Schedules)

0 continuation sheets attached to the Schedule of Real Property

B6B (Official Form 6B) (12/07)

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE B - PERSONAL PROPERTY

Except as directed below, list all personal property of the debtor of whatever kind. If the debtor has no property in one or more of the categories, place an "x" in the appropriate position in the column labeled "None." If additional space is needed in any category, attach a separate sheet properly identified with the case name, case number, and the number of the category. If the debtor is married, state whether husband, wife, both, or the marital community own the property by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community." If the debtor is an individual or a joint petitioner is filed, state the amount of any exemptions claimed only in Schedule C - Property Claimed as Exempt.

Do not list interests in executory contracts and unexpired leases on this schedule. List them in Schedule G - Executory Contracts and Unexpired Leases.

If the property is being held for the debtor by someone else, state that person's name and address under "Description and Location of Property." If the property is being held for a minor child, simply state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).

Type of Property	N O N E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
1. Cash on hand	X			
2. Checking, savings or other financial accounts, certificates of deposit, or shares in banks, savings and loan, thrift, building and loan, and homestead associations, or credit unions, brokerage houses, or cooperatives.		JP Morgan Chase Commercial Checking (XXXXXX2035 and XXXXXX0953)	-	77,681.19
		JP Morgan Chase XXXXXX3001)	-	4,078.14
		JP Morgan Chase - money market	-	0.00
3. Security deposits with public utilities, telephone companies, landlords, and others.		Deposit with RB Kendall Fee, LLC with respect to lease of commercial real property located at One Kendall Square, Cambridge, MA	-	66,754.38
		Security deposit with Pacific Bio-Material Management, Inc. for freezer storage of product	-	7,350.00
4. Household goods and furnishings, including audio, video, and computer equipment.	X			
5. Books, pictures and other art objects, antiques, stamp, coin, record, tape, compact disc, and other collections or collectibles.	X			
6. Wearing apparel.	X			
7. Furs and jewelry.	X			
8. Firearms and sports, photographic, and other hobby equipment.	X			
9. Interests in insurance policies. Name insurance company of each policy and itemize surrender or refund value of each.		Director & officer liability policy Chartis Policy No. 01-857-04-66 \$1,000,000 liability limit	-	Unknown
		Excess director & officer liability policy Admiral Insurance Co. Policy No. 61071591 \$1,000,000 liability limit	-	Unknown
Sub-Total >				155,863.71
(Total of this page)				

3 continuation sheets attached to the Schedule of Personal Property

B6B (Official Form 6B) (12/07) - Cont.

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE B - PERSONAL PROPERTY
(Continuation Sheet)

Type of Property	NON E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
		Excess director & officer liability policy Hudson Insurance Co. Policy No. HN-0303-3309 \$1,000,000 liability limit	-	Unknown
10. Annuities. Itemize and name each issuer.	X			
11. Interests in an education IRA as defined in 26 U.S.C. § 530(b)(1) or under a qualified State tuition plan as defined in 26 U.S.C. § 529(b)(1). Give particulars. (File separately the record(s) of any such interest(s). 11 U.S.C. § 521(c).)	X			
12. Interests in IRA, ERISA, Keogh, or other pension or profit sharing plans. Give particulars.	X			
13. Stock and interests in incorporated and unincorporated businesses. Itemize.		100% of equity in Inspiration FIX IV, Inc., a Delaware corporation (subsidiary has no assets, liabilities or operations)	-	Unknown
		100% of equity in Inspiration Biopharmaceuticals EU Ltd. (subsidiary serves as Debtor's legal representative for purposes of conducting clinical trials in Europe.)	-	Unknown
14. Interests in partnerships or joint ventures. Itemize.	X			
15. Government and corporate bonds and other negotiable and nonnegotiable instruments.	X			
16. Accounts receivable.	X			
17. Alimony, maintenance, support, and property settlements to which the debtor is or may be entitled. Give particulars.	X			
18. Other liquidated debts owed to debtor including tax refunds. Give particulars.	X			
19. Equitable or future interests, life estates, and rights or powers exercisable for the benefit of the debtor other than those listed in Schedule A - Real Property.	X			
			Sub-Total >	0.00
			(Total of this page)	

Sheet 1 of 3 continuation sheets attached to the Schedule of Personal Property

B6B (Official Form 6B) (12/07) - Cont.

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE B - PERSONAL PROPERTY
(Continuation Sheet)

Type of Property	N O N E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
20. Contingent and noncontingent interests in estate of a decedent, death benefit plan, life insurance policy, or trust.	X			
21. Other contingent and unliquidated claims of every nature, including tax refunds, counterclaims of the debtor, and rights to setoff claims. Give estimated value of each.		Funds advanced to CMC ICOS pursuant to commercial supply agreement	-	20,000,000.00
		Prepayment to CMC for clinical product	-	1,187,500.00
22. Patents, copyrights, and other intellectual property. Give particulars.		SEE EXHIBIT B22	-	Unknown
23. Licenses, franchises, and other general intangibles. Give particulars.		OBI-1 License/Sublicense, Development, and Commercialization Agreement, dated 1/20/10, whereby Ipsen granted to Debtor certain exclusive licenses/sublicenses to develop and commercialize OBI-1, as amended by agreement dated 8/16/12	-	Unknown
		Amended and Restated License Agreement, dated 11/28/08, between Univ of N.C. and the Debtor, whereby UNC granted the Debtor a license to develop and commercialize IB1001, as amended by Amendment No. 1 effective 6/14/12	-	Unknown
24. Customer lists or other compilations containing personally identifiable information (as defined in 11 U.S.C. § 101(41A)) provided to the debtor by individuals in connection with obtaining a product or service from the debtor primarily for personal, family, or household purposes.	X			
25. Automobiles, trucks, trailers, and other vehicles and accessories.	X			
26. Boats, motors, and accessories.	X			
27. Aircraft and accessories.	X			
28. Office equipment, furnishings, and supplies.		Furniture & Fixtures (Book Value)	-	62,093.19
		Computers & Phones (Book Value)	-	85,961.51
		Computer Software (Book Value)	-	29,793.43
			Sub-Total >	21,365,348.13
				(Total of this page)

Sheet 2 of 3 continuation sheets attached to the Schedule of Personal Property

B6B (Official Form 6B) (12/07) - Cont.

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE B - PERSONAL PROPERTY
(Continuation Sheet)

Type of Property	NON E	Description and Location of Property	Husband, Wife, Joint, or Community	Current Value of Debtor's Interest in Property, without Deducting any Secured Claim or Exemption
29. Machinery, fixtures, equipment, and supplies used in business.		Machinery and Equipment (Book Value)	-	49,589.11
30. Inventory.	X			
31. Animals.	X			
32. Crops - growing or harvested. Give particulars.	X			
33. Farming equipment and implements.	X			
34. Farm supplies, chemicals, and feed.	X			
35. Other personal property of any kind not already listed. Itemize.	X			

Sub-Total > 49,589.11
(Total of this page)
Total > 21,570,800.95

Sheet 3 of 3 continuation sheets attached to the Schedule of Personal Property

(Report also on Summary of Schedules)

EXHIBIT B22

List of Patents in Exhibit B22 includes patents owned, in whole or in part, by the Debtor as well as patents owned by third parties and subject to licensing agreements with the Debtor.

Inspiration Biopharmaceuticals, Inc Trademark List

INOBOXIS Ref: 4004-311835 **CTM**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : 009671215 Jun 27 2011
 App No : 009671215 Jan 19 2011 Registered
 RENEWAL DUE: Jan 19 2021

Class 5
Goods Pharmaceutical preparations for the treatment of hemophilia.

INOBOXIS Ref: 4000-311835 **United States of America**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : Pending
 App No : 85220702 Jan 19 2011
 RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations for the treatment of hemophilia

INSPIRATION BIOPHARMACEUTICALS Ref: 4042-311835 **Argentina**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : Instructed
 App No :
 RENEWAL DUE:

Class 5
Goods pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia

INSPIRATION BIOPHARMACEUTICALS Ref: 4041-311835 **Brazil**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : Pending
 App No : 840249314 Aug 29 2012
 RENEWAL DUE:

Class 5
Goods pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia

INSPIRATION BIOPHARMACEUTICALS Ref: 4044-311835 **Chile**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : Pending
 App No : 1023361 Aug 29 2012
 RENEWAL DUE:

Class 5
Goods pharmaceutical products and preparations to treat hemophilia

INSPIRATION BIOPHARMACEUTICALS Ref: 4045-311835 **Colombia**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : Pending
 App No : 12-147314 Aug 29 2012
 RENEWAL DUE:

Class 5
Goods pharmaceuticals, namely, pharmaceutical preparations for the treatment of haemophilia, pharmaceutical preparations

INSPIRATION BIOPHARMACEUTICALS Ref: 4047-311835 **CTM**
 Inspiration Biopharmaceuticals, Inc.
 Reg No : Pending
 App No : 11147238 Aug 29 2012
 RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia
Class	42
Goods	drug discovery services; pharmaceutical research and development services
Class	44
Goods	health care services; medical diagnostic services

INSPIRATION BIOPHARMACEUTICALS **Ref: 4039-311835** **Japan**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 2012-069811 Aug 29 2012
RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia

INSPIRATION BIOPHARMACEUTICALS **Ref: 4043-311835** **Mexico**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 1304377 Aug 29 2012
RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia

INSPIRATION BIOPHARMACEUTICALS **Ref: 4046-311835** **Russian Federation**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 2012730303 Aug 29 2012
RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of haemophilia, pharmaceutical preparations

INSPIRATION BIOPHARMACEUTICALS **Ref: 4040-311835** **South Africa**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 201223693 Aug 29 2012
RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of haemophilia, pharmaceutical preparations

INSPIRATION BIOPHARMACEUTICALS **Ref: 4037-311835** **Taiwan**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 101049194 Aug 29 2012
RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of haemophilia, pharmaceutical preparations

INSPIRATION BIOPHARMACEUTICALS **Ref: 4038-311835** **Turkey**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 201274043 Aug 29 2012
RENEWAL DUE:

Class	5
Goods	pharmaceuticals, namely, pharmaceutical preparations for the treatment of haemophilia, pharmaceutical preparations

INSPIRATION BIOPHARMACEUTICALS Ref: 4008-311835 United States of America
Inspiration Biopharmaceuticals, Inc. Abandoned
Reg No :
App No : 77402655 Feb 21 2008
RENEWAL DUE:

Class 5
Goods Pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia

INSPIRATION BIOPHARMACEUTICALS Ref: 4009-311835 United States of America
Inspiration Biopharmaceuticals, Inc. Pending
Reg No :
App No : 85555938 Feb 29 2012
RENEWAL DUE:

Class 5
Goods pharmaceuticals, namely, pharmaceutical preparations for the treatment of hemophilia.

IXALITY Ref: 4005-311835 CTM
Inspiration Biopharmaceuticals, Inc. Registered
Reg No : 009671231 Jun 27 2011
App No : 009671231 Jan 19 2011
RENEWAL DUE: Jan 19 2021

Class 5
Goods Pharmaceutical preparations for the treatment of hemophilia.

IXALITY Ref: 4001-311835 United States of America
Inspiration Biopharmaceuticals, Inc. Pending
Reg No :
App No : 85220709 Jan 19 2011
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations for the treatment of hemophilia

IXinity Ref: 4015-311835 Argentina
Inspiration Biopharmaceuticals, Inc. Pending
Reg No :
App No : 3165116 May 17 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXINITY Ref: 4014-311835 Australia
Inspiration Biopharmaceuticals, Inc. Pending
Reg No :
App No : 1480170 Mar 14 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXINITY Ref: 4013-311835 Brazil
Inspiration Biopharmaceuticals, Inc. Pending
Reg No :
App No : 904637328 Mar 23 2012
RENEWAL DUE:

Class 5

Goods Class 5 Pharmaceutical preparations

IXINITY **Ref: 4017-311835** **Canada**
 Inspiration Biopharmaceuticals, Inc. **Pending**
 Reg No :
 App No : 1568455 Mar 13 2012
 RENEWAL DUE:

Goods Class 5 (1) Pharmaceutical preparations.

IXinity **Ref: 4027-311835** **Chile**
 Inspiration Biopharmaceuticals, Inc. **Pending**
 Reg No :
 App No : 999711 Mar 23 2012
 RENEWAL DUE:

Goods Class 5 Pharmaceutical preparations

IXinity **Ref: 4016-311835** **China**
 Inspiration Biopharmaceuticals, Inc. **Pending**
 Reg No :
 App No : 10645298 Mar 20 2012
 RENEWAL DUE:

Goods Class 5 Pharmaceutical preparations

IXinity **Ref: 4029-311835** **Colombia**
 Inspiration Biopharmaceuticals, Inc. **Pending**
 Reg No :
 App No : 12079796 May 15 2012
 RENEWAL DUE:

Goods Class 5 Pharmaceutical preparations for the treatment of bleeding disorders

IXINITY **Ref: 4006-311835** **CTM**
 Inspiration Biopharmaceuticals, Inc. **Registered**
 Reg No : 009671249 Jun 27 2011
 App No : 009671249 Jan 19 2011
 RENEWAL DUE: Jan 19 2021

Goods Class 5 Pharmaceutical preparations for the treatment of hemophilia.

IXINITY **Ref: 4018-311835** **India**
 Inspiration Biopharmaceuticals, Inc. **Pending**
 Reg No :
 App No : 2299289 Mar 14 2012
 RENEWAL DUE:

Goods Class 5 Pharmaceutical preparations

IXinity **Ref: 4032-311835** **Indonesia**
 Inspiration Biopharmaceuticals, Inc. **Pending**
 Reg No :
 App No : D002012013996 Mar 27 2012
 RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXINITY **Ref: 4012-311835** **Israel**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 245198 Mar 14 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4011-311835** **Japan**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 2012-019936 Mar 15 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4035-311835** **Kazakhstan**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 57589 Mar 26 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4010-311835** **Korea South**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 4020120020248 Mar 27 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4031-311835** **Kuwait**
Inspiration Biopharmaceuticals, Inc. **Pending**
Reg No :
App No : 128765 Mar 27 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXINITY **Ref: 4019-311835** **Mexico**
Inspiration Biopharmaceuticals, Inc. **Registered**
Reg No : 1302878 Aug 9 2012
App No : 1258399 Mar 15 2012
RENEWAL DUE: Mar 15 2022

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4020-311835** **New Zealand**
Inspiration Biopharmaceuticals, Inc. **Registered**
Reg No : 955543 Sep 18 2012
App No : 955543 Mar 14 2012
RENEWAL DUE: Mar 14 2022

Class 5
Goods Pharmaceutical preparations

IXINITY **Ref: 4021-311835** **Norway**
Inspiration Biopharmaceuticals, Inc. Registered
Reg No : 266290 Jul 6 2012
App No : 201202805 Mar 14 2012
RENEWAL DUE: Mar 14 2022

Class 5
Goods Pharmaceutical preparations

Class 42
Goods Pharmaceutical research and development services

Class 44
Goods Medical services; medical treatment; health services; information relating to medical services, medical treatment and pharmaceutical preparations.

IXINITY **Ref: 4028-311835** **Peru**
Inspiration Biopharmaceuticals, Inc. Registered
Reg No : 190646 Aug 15 2012
App No : 487424 Mar 21 2012
RENEWAL DUE: Aug 15 2022

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4022-311835** **Russian Federation**
Inspiration Biopharmaceuticals, Inc. Pending
Reg No : Pending
App No : 2012707588 Mar 15 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4030-311835** **Saudi Arabia**
Inspiration Biopharmaceuticals, Inc. Pending
Reg No : Pending
App No : 180225 Mar 27 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4024-311835** **South Africa**
Inspiration Biopharmaceuticals, Inc. Pending
Reg No : Pending
App No : 201207095 Mar 19 2012
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations

IXinity **Ref: 4025-311835** **Switzerland**
Inspiration Biopharmaceuticals, Inc. Registered
Reg No : 627391 Mar 22 2012
App No : 627391 Mar 14 2012
RENEWAL DUE: Mar 14 2022

Class 5

Goods **Pharmaceutical preparations**

IXinity **Ref: 4026-311835** **Taiwan**
Inspiration Biopharmaceuticals, Inc.
Reg No : Pending
App No : 101017402 Apr 2 2012
RENEWAL DUE:

Class **5**
Goods **Pharmaceutical preparations**

IXinity **Ref: 4034-311835** **Thailand**
Inspiration Biopharmaceuticals, Inc.
Reg No : Pending
App No : 841121 Mar 27 2012
RENEWAL DUE:

Class **5**
Goods **pharmaceutical preparations for the treatment of hemophilia**

IXINITY **Ref: 4036-311835** **Ukraine**
Inspiration Biopharmaceuticals, Inc.
Reg No : Pending
App No : m201204919 Mar 22 2012
RENEWAL DUE:

Class **5**
Goods **Pharmaceutical preparations**

IXINITY **Ref: 4002-311835** **United States of America**
Inspiration Biopharmaceuticals, Inc.
Reg No : Pending
App No : 85220714 Jan 19 2011
RENEWAL DUE:

Class **5**
Goods **Pharmaceutical preparations for the treatment of hemophilia**

IXinity **Ref: 4033-311835** **Vietnam**
Inspiration Biopharmaceuticals, Inc.
Reg No : Pending
App No : 4201205679 Mar 27 2012
RENEWAL DUE:

Class **5**
Goods **Pharmaceutical preparations**

IXinity / IXINITY (series of 2) **Ref: 4023-311835** **Singapore**
Inspiration Biopharmaceuticals, Inc.
Reg No : Pending
App No : T1203520H Mar 15 2012
RENEWAL DUE:


Class **5**
Goods **Pharmaceutical preparations**

JUBIXYS **Ref: 4007-311835** **CTM**
Inspiration Biopharmaceuticals, Inc.
Reg No : 009671223 Jun 27 2011 Registered
App No : 009671223 Jan 19 2011
RENEWAL DUE: Jan 19 2021

Class 5
Goods Pharmaceutical preparations for the treatment of hemophilia.

JUBIXYS **Ref: 4003-311835** **United States of America**
Inspiration Biopharmaceuticals, Inc. Pending
Reg No :
App No : 85220704 Jan 19 2011
RENEWAL DUE:

Class 5
Goods Pharmaceutical preparations for the treatment of hemophilia

TM  Administrator - END OF REPORT

IPPO WebTMS: printed Oct 23 2012 10:21:45 AM

FACTOR IX

Factor IX

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
CORRELATION OF SNPS IN THE VITAMIN K EPOXIDE REDUCTASE GENE AND WARFARIN DOSAGE (METHODS AND COMPOSITIONS FOR VITAMIN K EPOXIDE REDUCTASE) (UNC)							
0024(311835)	04-0007	UNC	60/505,527	5470-401PR	US PROV	9/23/2003	EXPIRED
0024(311835)	04-0007	UNC	PCT/US04/031481	5470-401WO	PCTY	9/23/2004	EXPIRED
0024(311835)	04-0007	UNC	10/573,131 7,687,233	5470-401	US	4/18/2006	ALLOWED
0024(311835)	04-0007	UNC	11/516,229 7,524,665	5470-401CT	US CON	9/6/2006	EXPIRES 09/23/2024
0024(311835)	04-0007	UNC	11/699,930 7,482,141	5470-401CT2	US CON	1/30/2007	EXPIRES 09/23/2024
0024(311835)	04-0007	UNC	11/787,072 7,645,602	5470-401P	US CIP	4/13/2007	EXPIRES 09/23/2024
0024(311835)	04-0007	UNC	12/612,154	5470-401PCT2	US CON	11/4/2009	PENDING
0024(311835)	04-0007	UNC	2004275828	5470-401AU	AU	9/23/2004	PENDING
0024(311835)	04-0007	UNC	2539434	5470-401CA	CA	9/23/2004	PENDING
0024(311835)	04-0007	UNC	4789039.7	5470-401EP	EP	9/23/2004	PENDING
0024(311835)	04-0007	UNC	7109353.8	5470-401EP2	EP DIV	9/23/2004	PENDING
0024(311835)	04-0007	UNC	2006528251	5470-401JP	JP	9/23/2004	PENDING
0024(311835)	04-0007	UNC	61140030	5470-401HK	HK	9/23/2004	PENDING
0024(311835)	04-0007	UNC	81036847	5470-401HK2	HK DIV	9/23/2004	PENDING
0024(311835)	04-0007	UNC	11156979.4	5470-401EP4	EP DIV	9/23/2004	PENDING
HUMAN FACTOR IX VARIANTS WITH AN EXTENDED HALF LIFE (UNC+ INSPARATION co-owned)							

Factor IX

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
0027(311835)	08-0033	UNC	60/999,035	5470-476PR	US PROV	10/15/2007	EXPIRED
0027(311835)	08-0033	UNC	12/734,181 2011/0154516	5470-476	US	4/15/2010	PUBLISHED 06/23/2011
0027(311835)	08-0033	UNC	PCT/US08/011754 WO09051717	5470-476WO	PCT	10/15/2008	EXPIRED
0027(311835)	08-0033	UNC	2008311793	5470-476AU	AU	10/15/2008	
0027(311835)	08-0033	UNC	2702363	5470-476CA	CA	10/15/2008	
0027(311835)	08-0033	UNC	2,0088E+12	5470-476CN	CN	10/15/2008	
0027(311835)	08-0033	UNC	8839270.9	5470-476EP	EP	10/15/2008	
0027(311835)	08-0033	UNC	1739KOLNP2010	5470-476IN	IN	10/15/2008	
0027(311835)	08-0033	UNC	2010529936	5470-476JP	JP	10/15/2008	
VITAMIN K-DEPENDENT CARBOXYLASE (UNC)							
0026(311835)	90-62	UNC	07/697,427	5470-24	US	5/8/1991	ABANDONED
0026(311835)	90-62	UNC	07/756,250 5,268,275	5470-34	US	9/9/1991	EXPIRED 12/7/2010
0026(311835)	90-62	UNC	PCT/US92/003853	5470-34.1WO	PCT	5/8/1992	EXPIRED
0026(311835)	90-62	UNC	2102702	5470.34.4C A	CA	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 0587742	5470-34.2EP	EP	5/18/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 692325441	5470-34.2DE	DE	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2DK	DK	5/8/1992	EXPIRES 05/08/2012

Factor IX

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2FR	FR	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2GB	GB	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2ES	SE	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC		5470-34.2AT	AT	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2BE	BE	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2CH	CH	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2ES	ES	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2GR	GR	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2IT	IT	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2LI	LI	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2LU	LU	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2MC	MC	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2NL	NL	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2AU	AU	5/8/1992	
METHODS AND COMPOSITIONS FOR PRODUCING VITAMIN K-DEPENDENT PROTEINS (UNC)							
0025(311835)	04-0007	UNC	11/885,067	5470-472	US	3/15/2005	PENDING
0025(311835)	04-0007	UNC	PCT/US05/008643	5470-401WO2	PCT	3/15/2005	EXPIRED

Factor IX

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
0025(311835)	04-0007	UNC	2005329450	5470-472AU	AU	3/15/2005	PENDING
0025(311835)	04-0007	UNC	5733161.3	5470-472EP	EP	3/15/2005	PENDING
0025(311835)	04-0007	UNC	2601574	5470-472CA	CA	3/15/2005	Abandoned
0025(311835)	04-0007	UNC	20080501851	5470-472JP	JP	3/15/2005	PENDING
0025(311835)	04-007AU	UNC	TBD	5470-472AU2	AU	4/10/2012	PENDING
METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS (Inspiration-UNC Co-Owned)							
90160P(311835)	INSPI.024PR	Inspiration	61/256,802		US PROV	10/30/2009	EXPIRED
90160WO(311835)	INSPI.024WO	Inspiration	PCT/US2010/054581		PCT	10/28/2010	PUBLISHED Nationalized
90160US(311835)	INSPI.024NP	Inspiration	13/459,743		US	4/30/2012	Published
90160EP(311835)	INSPI.024WO	Inspiration	10827499.4		EP	10/28/2010 (PCT date)	Published
90160JP(311835)	TBD	Inspiration	awaiting		JP	10/28/2010 (PCT date)	Pending
STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE (Inspiration Owned)							
90203(311835)	INSPI.015NP	Inspiration	12/744,017		US	5/28/2010	PUBLISHED
90203P(311835)	INSPI.015PR	Inspiration	61/016,230		US PROV	12/21/2007	CLOSED
90203WO(311835)	INSPI.015VPC	Inspiration	PCT/US2008/087031 (WO2009/082648)		PCT	12/16/2008	CLOSED

Factor IX

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
90203AU(311835)	INSP1.015VAU	Inspiration	2008340304		AU	12/16/2008	Pending
90203BR(311835)	INSP1.015VBR	Inspiration	PI0821591-0		BR	12/16/2008	PENDING
90203CA(311835)	INSP1.015VCA	Inspiration	2707032		CA	12/16/2008	Pending
90203CN(311835)	INSP1.015VCN	Inspiration	2.0088E+11		CN	12/16/2008	Pending
90203EP(311835)	INSP1.015VEP	Inspiration	8864646.8		EP	12/16/2008	PUBLISHED
90203IN(311835)	INSP1.015VIN	Inspiration	1530/MUMNP/2010		IN	12/16/2008	Pending-published
90203JP(311835)	INSP1.015VJP	Inspiration	2010-539710		JP	12/16/2008	Pending-PUBLISHED
90203RU(311835)	INSP1.015VRU	Inspiration	2010122379		RU	12/16/2008	Pending
METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODS (Inspiration-UNC co-Owned)							
90204(311835)	INSP1.002A	Inspiration	11/643,563 (co-owned with UNC)		US	12/21/2006	Published
90204P(311835)	INSP1.002PR	Inspiration	607/52,642		US Prov	12/21/2005	Closed
90204WO(311835)	INSP1.002VPC	Inspiration	PCT/JUS2006/048954		PCT	12/21/2006	Closed
90204AU(311835)	INSP1.002VAU	Inspiration	2006331501		AU	12/21/2006	Pending Acceptance 8/15/2013
90204EP(311835)	INSP1.002VEP	Inspiration	6848864.2		EP	12/21/2006	Published
90204EPDIV(311835)	INSP1.002VEPD1	Inspiration	11157194.9		EP	12/21/2006	Published
90204JP(311835)		Inspiration	2008-547588		JP	12/21/2006	Pending
90204HKDIV(311835)	INSP1.002HK	Inspiration	12104533.2		HK	5/9/2012	Published
90204CA(311835)	INSP1.002VCA	Inspiration	2,633,661		CA	12/21/2006	Pending

Factor IX

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SALIC ACID CONTENT AND METHODS OF PREPARING SAME (Inspiration UNC co-Owned)							
90207(311835)	INSPI.008NP	Inspiration	121597,456		US	10/23/2009	PUBLISHED
90207P(311835)	INSPI.008PR	Inspiration	60/914,281		US PROV	4/26/2007	CLOSED
90207WO(311835)	INSPI.008VPC	Inspiration	PCT/US2008/061822		PCT	4/28/2008	EXPIRED
90207AU(311835)	INSPI.008VAU	Inspiration	2008245524		AU	4/28/2008	Pending
90207CA(311835)	INSPI.008VCA	Inspiration	2683423		CA	4/28/2008	Pending
90207EP(311835)	INSPI.008VEP	Inspiration	8747060.5		EP	4/28/2008	Pending
90207JP(311835)	INSPI.008VJP	Inspiration	2010-506563		JP	4/28/2008	PUBLISHED-pending
90207DIVEP(311835)		Inspiration	12170422.5		EP	4/28/2012	Pending-published

RECOMBINANT HUMAN FVIII

Factor VIII

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	ATTY REF NO.	Former ATTY REF NO	GS ID / GS Ref No	Country	Filing Date	NOTE
METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODS (Inspiration-UNC co-Owned)									
90204(311835)	INSP1.002A	Inspiration	11/643,563 (co-owned with UNC)				US	12/21/2006	Published
90204P(311835)	INSP1.002PR	Inspiration	60/752,642				US Prov	12/21/2005	Closed
90204WO(311835)	INSP1.002VPC	Inspiration	PCT/US2006/048954				PCT	12/21/2006	Closed
90204AU(311835)	INSP1.002VAU	Inspiration	2006331501				AU	12/21/2006	Pending Acceptance 8/15/2013
90204EP(311835)	INSP1.002VEP	Inspiration	6848864.2				EP	12/21/2006	Published
90204EPPDIV(311835)	INSP1.002VEPD1	Inspiration	11157194.9				EP	12/21/2006	Published
90204JP(311835)		Inspiration	2008-547588				JP	12/21/2006	Pending
90204HKDVI(311835)	INSP1.002HK	Inspiration	12104533.2				HK	5/9/2012	Published
90204CA(311835)	INSP1.002VCA	Inspiration	2,633,661				CA	12/21/2006	Pending
A1 DOMAIN MUTATED FVIII (U of Michigan)									
0029(311835)	1184p1c1	UoM	09/819,098 6,838,437	25991- 18498			US	4/11/2011	EXPIRES 05/17/2018
0029(311835)	1184p1c2	UoM	10/974,534 7,459,534	25991- 18406			US	10/26/2004	EXPIRES 04/24/2017
0029(311835)	2293p2c1	UoM	11/455,116 US2006/0293238	25991- 18407			US	6/16/2006	ALLOWED WILL ISSUE 5/22/2012 as U.S.
0029(311835)	1184p1	UoM	538216/1997 3987114	25991- 18430			JP	4/24/1997	ABANDONED
0029(311835)	2293p2c2	UoM	13/015,043	25991- 18408			US	1/27/2011	PENDING
0029(311835)	1184p1	UoM	6004484.9	25991- 18489			EP	12/5/2005	PENDING
0029(311835)	1184p1	UoM	97927596.3 0910628	25991- 18485			GB	4/24/1997	EXPIRES 04/24/2017
0029(311835)	1184p1	UoM	97927596.3 0910628	25991- 18494			FR	4/24/1997	EXPIRES 4/24/2017

Factor VIII

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY/REF NO.	Former ATTY REF NO	GS ID / GS Ref No	Country	Filing Date	NOTE
0029(311835)	1184p1	UoM	97927596.3 0910628	25991-18495			DE	4/24/1997	EXPIRES 04/24/2017
ADD OTHER COUNTRIES 0029(311835)	2299p2c2	UoM	13/542,010	25991-18409					Divisional app of 13/015,043
PROCESS FOR IMPROVING FVIII PRODUCTION (U of Michigan and Inspiration Co-owned)									
91113(311835) (formerly)	3392	UoM	11/771,400 US2008/007025	25991-39201			US	6/29/2007	ABANDONED
0028(311835)	3392	UoM	PCT/US07/072506	25991-39225			PCT	6/29/2007	nationalized
0028(311835)	3392c1	UoM	12/758,457	25991-39203			US	4/12/2010	RCE filed 6/13/2012 Pending
91113CIP(311835) (formerly)	3392p1	UoM	12/252,024 US2009/0203077	25991-39202			US CIP	10/15/2008	PENDING and published
91113AU(311835) (formerly)	3392	UoM	2007269233	25991-39240			AU	6/29/2007	GRANTED
91113EP(311835) (formerly)	3392	UoM	7812491.4	25991-39280			EP	6/29/2007	PENDING
91113EPDIV(311835)		UoM	12164874.5				EP		Pending
91113CA(311835) (formerly)	3392	UoM	2656558	25991-39250			CA	6/29/2007	PENDING
91113JP(311835) (formerly)	3392	UoM	2009518576	25991-39230			JP	6/29/2007	PENDING-published
91113CIP1 formerly 0028(311835)	3392C1P1	UoM	13/153,040	25991-39204			US	6/3/2011	PENDING
0028(311835)	Awaiting	UoM	PCT/US2012/040376				WO	6/1/2012	Pending
MODIFIED FACTOR VIII (Emory owned; licensed to Ipsen; sub-licensed to Inspiration)									
Highlighted cases include claims to human/porcine Hybrid Factor VIII constructs									
0021(311835)	91023DIV/CL	Emory	08/251,937 5,583,209	5/31/1994			US	75-95C US	
0021(311835)	91023US CL	Emory	07/864,004 5,364,771	4/7/1992			US	75-95 US	

Factor VIII

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Former ATTY REF NO	GS ID / GS Ref No	Country	Filing Date	NOTE
0021(311835)	96054AT CL	Emory	97933180.8 0939767		6/26/1997	75-95F AT			
0021(311835)	96054AU CL	Emory	3643397 717686		6/26/1997	75-95F AU			
0021(311835)	96054BE CL	Emory	97933180.8 0939767		6/26/1997	75-95F BE			
0021(311835)	96054CA CL	Emory	2258502 2,258,502		6/26/1997	75-95F CA			
0021(311835)	96054CH CL	Emory	97933108.8 0939767		6/26/1997	75-95F CH			
0021(311835)	96054DE CL	Emory	97933108.8 0939767		6/26/1997	75-95F DE			
0021(311835)	96054DK CL	Emory	97933180.8 0939767		6/26/1997	75-95F DK			
0021(311835)	96054EP CL	Emory	97933180.8 0939767		6/26/1997	75-95F EP			
0021(311835)	96054ES CL	Emory	97933180.8 0939767		6/26/1997	75-95F ES			
0021(311835)	96054FI CL	Emory	97933180.8 0939767		6/26/1997	95-95F FI			
0021(311835)	96054FR CL	Emory	97933180.8 0939767		6/26/1997	75-95F FR			
0021(311835)	96054GB CL	Emory	97933180.8 0939767		6/26/1997	75-95F GB			
0021(311835)	96054GR CL	Emory	97933180.8 0939767		6/26/1997	75-95F GR			
0021(311835)	96054HK CL	Emory	00101412.8 1022480B		6/26/1997	75-95F HK			
0021(311835)	96054IE CL	Emory	97933180.8 0939767		6/26/1997	75-95F IE			
0021(311835)	96054IT CL	Emory	97933180.8 0939767		6/26/1997	75-95F IT			
0021(311835)	96054JP CL	Emory	2004-02795 3683897		6/26/1997	75-95F1 JP			
0021(311835)	96054LU CL	Emory	97933180.8 0939767		6/26/1997	75-95F LU			
0021(311835)	96054LU CL	Emory	97933180.8 0939767		6/26/1997	75-95F MC			
0021(311835)	96054NL CL	Emory	97933180.8 0939767		6/26/1997	75-95F NL			
0021(311835)	96054PCT CL	Emory	9711155 97149725		6/26/1997	75-95F WO			
0021(311835)	96054PT CL	Emory	97933180.8 0939767		6/26/1997	75-95F PT			

Factor VIII

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Former ATTY REF NO.	GS ID / GS Ref No	Country	Filing Date	NOTE
0021(311835)	96054PT CL	Emory	97933180.8 0939767		6/26/1997	75-95F SE			
0021(311835)	96054US CL	Emory	08/671,707 5,859,204		6/26/1997	75-95F US			
0021(311835)	98026AU CL	Emory	29956/99 747644		3/10/1999	75-95G AU			
0021(311835)	98026CA CL	Emory	2322508		3/10/1999	75-95G CA			
0021(311835)	98026CZ CL	Emory	PV 2000-32 300959		3/10/1999	75-95G CZ			
0021(311835)	98026IL CL	Emory	138281	138281	3/10/1999	75-95G IL			
0021(311835)	98026KR CL	Emory	2000-70101 0490612		3/10/1999	75-95G KR			
0021(311835)	98026MX CL	Emory	2005	00807	3/10/1999	75-95G1 MX			
0021(311835)	98026MX CL	Emory	008829	230901	3/10/1999	75-95G MX			
0021(311835)	98026NZ CL	Emory	506771		3/10/1999	75-95G NZ			
0021(311835)	98026US CL	Emory	09/037,601 6180371		3/10/1998	75-95G US			
0021(311835)	99051US CL 02075	Emory	10/938,414 7,122,634		9/10/2004	75-95L US			

RECOMBINANT PORCINE FACTOR VIII (OBI-1)

OBI-1

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
STABLE PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VIII (IPSEN Owned)							
90202(311835)	INSPI.036NP	Inspiration	10/507.956/ 7,790,680	US	9/14/2004		Issued 9/7/10
90202WO(311835)	INSPI.036WO	Inspiration	PCT/GB2003/001297 WO2003/080108	PCT	3/26/2003		Closed
90202AR(311835)	INSPI.036AR	Inspiration	PO30101024	AR	3/25/2003		Published Pending
90202AT(311835)	RS 326-AT-EPT	Inspiration	3712418.7	AT	3/26/2003		granted
90202AU(311835)	INSPI.036AU	Inspiration	2003217030/ 2003217030	AU	3/26/2003		ISSUED 3/19/09
90202BE(311835)		Inspiration	3712418.7	BE	3/26/2003		Granted
90202BR(311835)	INSPI.036BR	Inspiration	PI0308442-6	BR	3/26/2003		Pending
90202CA(311835)	INSPI.036CA	Inspiration	2480226	CA	3/26/2003		Granted
90202CH(311835)		Inspiration	3712418.7	CH	3/26/2003		Granted
90202CL(311835)	INSPI.036CL	Inspiration	0583-2003/ 46,300	CL	3/26/2003		ISSUED 1/15/10
90202CN(311835)	INSPI.036CN	Inspiration	3806991.1	CN	3/26/2003		Pending
90202CZ(311835)		Inspiration	3712418.7	CZ	3/26/2003		granted
90202DE(311835)		Inspiration	3712418.7	DE	3/26/2003		Granted
90202DK(311835)		Inspiration	3712418.7	DK	3/26,2003		Granted
90202EP(311835)	INSPI.036EP	Inspiration	03712418.7/ 1490095	EP	3/26/2003		ISSUED 9/18/10
90202EPDIV(311835)	INSPI.036EPD1	Inspiration	10172869.9	EP	3/26/2003		ABANDONED
90202ES(311835)		Inspiration	3712418.7	ES	3/26/2003		granted
90202FI(311835)		Inspiration	3712418.7	FI	3/26/2003		Granted

OBI-1

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
90202FR(311835)		Inspiration	3712418.7	FR	3/26/2003		Granted
		Inspiration	207092.8	GB	3/26/2003		
90202GB(311835)		Inspiration	3712418.7	GB	3/26/2003		
90202GR(311835)		Inspiration	3712418.7	GR	3/26/2003		Granted
90202HK(311835)	INSP1.036HK	Inspiration	6100540.9	HK	3/26/2003		PUBLISHED
90202HR(311835)	INSP1.036HR	Inspiration	P20040882 A	HR	3/26/2003		PUBLISHED
90202HU(311835)		Inspiration	3712418.7	HU			37706
90202IE(311835)		Inspiration	3712418.7	IE			37706
90202IL(311835)	INSP1.036IL	Inspiration	163849/ 163849	IL	3/26/2003		ISSUED 3/31/11
90202IN(311835)	INSP1.036IN	Inspiration	2592/DELNP/2004	IN	3/26/2003		PENDING
90202IS(311835)	INSP1.036IS	Inspiration	7458	IS	3/26/2003		CLOSED
90202HK(311835)		Inspiration	3712418.7	IT	3/26/2003		
90202JP(311835)	INSP1.036JP	Inspiration	2003-577934	JP	3/26/2003		ABANDONED
90202JPDIV(311835)	INSP1.036JPD1	Inspiration	2011-002185	JP	3/26/2003		PUBLISHED
90202KR(311835)	INSP1.036KR	Inspiration	10-2004-7015295	KR	3/26/2003		ABANDONED
90202LU(311835)		Inspiration	3712418.7	LU	3/26/2003		Granted
90202MX(311835)	INSP1.036MX	Inspiration	PA/A/04/009275/ 265856	MX	3/26/2003		ISSUED 4/8/09
90202MY(311835)	INSP1.036MY	Inspiration	P120030960	MY	3/26/2003		PENDING
90202NL(311835)		Inspiration	3712418.7	NL	3/26/2003		Granted

OBI-1

EMP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
90202NO(311835)	INSP1.036NO	Inspiration	20044305/ 328450	NO	3/26/2003		Granted
90202NZ(311835)	INSP1.036NZ	Inspiration	535032/ 535032	NZ	3/26/2003		ISSUED 7/13/06
90202PL(311835)	INSP1.036PL	Inspiration	P-372414/ P-372414	PL	3/26/2003		ISSUED 9/16/10
90202PT(311835)		Inspiration	3712418.7	PT	3/26/2003		Granted
90202RO(311835)		Inspiration	3712418.7	RO	3/26/2003		Granted
90202RU(311835)	INSP1.036RU	Inspiration	2004131556/ 2314825	RU	3/26/2003		ISSUED 1/20/08
90202SE(311835)		Inspiration	3712418.7	SE	3/26/2003		Granted
90202SG(311835)	INSP1.036SG	Inspiration	200405157-9/ 106423	SG	3/26/2003		ISSUED 11/30/06
90202TH(311835)	INSP1.036TH	Inspiration	81195	TH	3/26/2003		Granted
90202TR(311835)		Inspiration	3712418.7	TR	3/26/2003		
90202TW(311835)	INSP1.036TW	Inspiration	92105665/ 1285106	TW	3/14/2003		ISSUED 8/11/07
MODIFIED FACTOR VIII (Emory owned, licensed to Ipsen, sub-licensed to Inspiration)							
Highlighted cases include claims to human/porcine Hybrid Factor VIII constructs							
0021(311835)	2075	Emory	11/550,366 7,560,107		10/17/2006	75-95M US	
0021(311835)	01026 CON CL	Emory	12/491,734		6/25/2009	75-95N US	ABANDONED
0021(311835)	01026 CON CL	Emory	13/431,085		3/27/2012	75-95O	COMPLETED??
0021(311835)	01026AL CL	Emory	01910853.9 1280540		2/16/2001	75-95I AL	
0021(311835)	01026AT CL	Emory	01910853.9 1280540		2/16/2001	75-95I AT	

OBI-1

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
0021(311835)	01026AU CL	Emory	2001238416 2001238416		2/16/2001	75-951 AU	
0021(311835)	01026BE CL	Emory	0191085.9 1280540		2/16/2001	75-951 BE	
0021(311835)	01026BR CL	Emory	PI0109131-0		2/16/2001	75-951 BR	
0021(311835)	01026CA CL	Emory	2400295		2/16/2001	75-951 CA	
0021(311835)	01026CH CL	Emory	01910853.9 1280540		2/16/2001	75-951 CH	
0021(311835)	01026CN CL	Emory	01806317.9 01806317.9		2/16/2001	75-951 CN	
0021(311835)	01026CY CL	Emory	01910853.9 1280540		2/16/2001	75-951 CY	
0021(311835)	01026CZ CL	Emory	PV 2002-33 298250		2/16/2001	75-951 CZ	
0021(311835)	01026DE CL	Emory	01910853.9 1280540		2/16/2001	75-951 DE	
0021(311835)	01026DK CL	Emory	01910853.9 1280540		2/16/2001	75-951 DK	
0021(311835)	01026EE CL	Emory	P200200510 05075		2/16/2001	75-951 EE	
0021(311835)	01026EP CL	Emory	0191085.9 1280540		2/16/2001	75-951 EP	
0021(311835)	01026ES CL	Emory	0191085.9 1280540		2/16/2001	75-951 ES	
0021(311835)	01026FI CL	Emory	0191085.9 1280540		2/16/2001	75-951 FI	
0021(311835)	01026FR CL	Emory	01910853.9 1280540		2/16/2001	75-951 FR	
0021(311835)	01026GB CL	Emory	01910853.9 1280540		2/16/2001	75-951 GB	
0021(311835)	01026GR CL	Emory	01910853.9 1280540		2/16/2001	75-951 GR	
0021(311835)	01026HK CL	Emory	03103224.9 1051004	HK	2/16/2001	75-951 HK	
0021(311835)	01026HU CL	Emory	P03000586		2/16/2001	75-951 HU	

OBI-1

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
0021(311835)	01026IE CL	Emory	01910853.9 1280540		2/16/2001	75-95I IE	
0021(311835)	01026IL CL	Emory	151371 151371		2/16/2001	75-95I IL	
0021(311835)	01026IN 1 CL	Emory	1383/DEL/2 242282		2/16/2001	75-95I1 IN	
0021(311835)	01026IN CL	Emory	IN/PCT/200 231640		2/16/2001	75-95I IN	
0021(311835)	01026IT CL	Emory	01910853.9 1280540		2/16/2001	75-95I IT	
0021(311835)	01026JP CL	Emory	2001-56667 4044337		2/16/2001	75-95I JP	
0021(311835)	01026KR CL	Emory	10-2002-70 485525		2/16/2001	75-95I KR	
0021(311835)	01026LT CL	Emory	01910853.9 1280540		2/16/2001	75-95I LT	
0021(311835)	01026LU CL	Emory	01910853.9 1280540		2/16/2001	75-95I LU	
0021(311835)	01026LV CL	Emory	01910853.9 1280540		2/16/2001	75-95I LV	
0021(311835)	01026MC CL	Emory	01910853.9 1280540		2/16/2001	75-95I MC	
0021(311835)	01026ME	Emory	P-82/09		2/16/2001	75-95I ME	
0021(311835)	01026MX CL	Emory	PA/a/2002 265063		2/16/2001	75-95I MX	
0021(311835)	01026NL CL	Emory	01910853.9 1280540		2/16/2001	75-95I NL	
0021(311835)	01026NO CL	Emory	2002 4296		2/16/2001	75-95I NO	Issued
0021(311835)	01026NZ CL	Emory	520799		2/16/2001	75-95I NZ	
0021(311835)	01026PCT CL	Emory	01/05076 01/68109		2/16/2001	75-95I WO	
0021(311835)	01026PL CL	Emory	P359672 202936		2/16/2001	75-95I PL	
0021(311835)	01026PT CL	Emory	01910853.9 1280540		2/16/2001	75-95I PT	

OBI-1

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
0021(311835)	01026RO CL	Emory	01910853.9 1280540		2/16/2001	75-95I RO	
0021(311835)	01026RU CL	Emory	2002124123 2285724		2/16/2001	75-95I RU	
0021(311835)	01026SE CL	Emory	01910853.9 1280540		2/16/2001	75-95I SE	
0021(311835)	01026SG CL	Emory	200204895 91075		2/16/2001	75-95I SG	
0021(311835)	01026SI CL	Emory	01910853.9 1280540		2/16/2001	75-95I SI	
0021(311835)	01026SK CL	Emory	PP 1439-20 286205		2/16/2001	75-95I SK	
0021(311835)	01026TR CL	Emory	01910853.9 1280540		2/16/2001	75-95I TR	
0021(311835)	01026UA CL	Emory	2002097145 75064		2/16/2001	95-95I UA	
0021(311835)	01026US CL	Emory	09/523.656 6458563		3/10/2000	75-95I US	
0021(311835)	01026YU CL	Emory	P-680.02 50364		2/16/2001	75-95I RS	
0021(311835)	01026ZA CL	Emory	2002/6810 2002/6810		2/16/2001	75-95I ZA	
0021(311835)	02075US CL	Emory	10/187.319 7,012,132		6/28/2002	75-95K US	
0021(311835)	91023DIV/CL	Emory	08/251.937 5,583,209		5/31/1994	75-95C US	
0021(311835)	91023US CL	Emory	07/864.004 5,364,771		4/7/1992	75-95 US	
0021(311835)	94015US CL	Emory			3/11/1994	75-95B US	
0021(311835)	96054AT CL	Emory	97933180.8 0939767		6/26/1997	75-95FAT	
0021(311835)	96054AU CL	Emory	36433/97 717686		6/26/1997	75-95F AU	
0021(311835)	96054BE CL	Emory	97933180.8 0939767		6/26/1997	75-95F BE	
0021(311835)	96054CA CL	Emory	22588502 2,258,502		6/26/1997	75-95F CA	

OBI-1

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
0021(311835)	96054CH CL	Emory	97933108.8 0939767		6/26/1997	75-95F CH	
0021(311835)	96054DE CL	Emory	97933108.8 0939767		6/26/1997	75-95F DE	
0021(311835)	96054DK CL	Emory	97933180.8 0939767		6/26/1997	75-95F DK	
0021(311835)	96054EP CL	Emory	97933180.8 0939767		6/26/1997	75-95F EP	
0021(311835)	96054ES CL	Emory	97933180.8 0939767		6/26/1997	75-95F ES	
0021(311835)	96054FI CL	Emory	97933180.8 0939767		6/26/1997	95-95F FI	
0021(311835)	96054FR CL	Emory	97933180.8 0939767		6/26/1997	75-95F FR	
0021(311835)	96054GB CL	Emory	97933180.8 0939767		6/26/1997	75-95F GB	
0021(311835)	96054GR CL	Emory	97933180.8 0939767		6/26/1997	75-95F GR	
0021(311835)	96054HK CL	Emory	00101412.8 1022480B		6/26/1997	75-95F HK	
0021(311835)	96054IE CL	Emory	97933180.8 0939767		6/26/1997	75-95F IE	
0021(311835)	96054IT CL	Emory	97933180.8 0939767		6/26/1997	75-95F IT	
0021(311835)	96054JP CL	Emory	2004-02795 3683897		6/26/1997	75-95F1 JP	
0021(311835)	96054LU CL	Emory	97933180.8 0939767		6/26/1997	75-95F LU	
0021(311835)	96054LU CL	Emory	97933180.8 0939767		6/26/1997	75-95F MC	
0021(311835)	96054NL CL	Emory	97933180.8 0939767		6/26/1997	75-95F NL	
0021(311835)	96054PCT CL	Emory	97111155 97149725		6/26/1997	75-95F WO	
0021(311835)	96054PT CL	Emory	97933180.8 0939767		6/26/1997	75-95F PT	
0021(311835)	96054PT CL	Emory	97933180.8 0939767		6/26/1997	75-95F SE	

OBI-1

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No	NOTE
0021(311835)	96054US CL	Emory	08/671,707 5,859,204		6/26/1997	75-95F US	
0021(311835)	98026AU CL	Emory	29956/99 747644		3/10/1999	75-95G AU	
0021(311835)	98026CA CL	Emory	2322508		3/10/1999	75-95G CA	
0021(311835)	98026CZ CL	Emory	PV 2000-32 300959		3/10/1999	75-95G CZ	
0021(311835)	98026IL CL	Emory	138281 138281		3/10/1999	75-95G IL	
0021(311835)	98026KR CL	Emory	2000-70101 0490612		3/10/1999	75-95G KR	
0021(311835)	98026MX CL	Emory	2005 00807		3/10/1999	75-95G1 MX	
0021(311835)	98026MX CL	Emory	008829 230901		3/10/1999	75-95G MX	
0021(311835)	98026NZ CL	Emory	506771 506771		3/10/1999	75-95G NZ	
0021(311835)	98026US CL	Emory	09/037,601 6180371		3/10/1998	75-95G US	
0021(311835)	99051US CL 02075	Emory	10/938,414 7,122,634		9/10/2004	75-95L US	
METHODS OF ADMINISTERING PORCINE B-DOMAINLESS FVIII (IPSEN/EMORY Co-owned)							
0022(311835)	IBEM 001-EP-EPT	Ipsen	574319.8	EP	4/28/2005	94-03 EP	EXPIRES 4/28/2025
0022(311835)	IBEM-001-HK-FPR	Ipsen	7108636.6	HK	4/28/2005	94-03HK	EXPIRES 4/28/2025
0022(311835)	IBEM 001-JP-PCT	Ipsen	2007-511442	JP	4/28/2005	94-03 JP	EXPIRES 4/28/2025
0022(311835)	IBEM 001-US- CIP11	Ipsen	11/549,049 7,576,181	US CIP	10/12/2006	94-03 US	EXPIRES 4/28/2025
0022(311835)	IBEM 001-US- CNT11	Ipsen	13/356,437	US DIV	1/23/2012	94-03B	
0022(311835)	IBEM 001-US- DIV11	Ipsen	12/496,516 8,101,718	US DIV	7/1/2009	94-03A US	EXPIRES 7/1/2029

OBI-1

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	Country	Filing Date	GS ID / GS Ref No.	NOTE
0022(311835)	IBEM 001-US-PSP	Ipsen	60/568,015	US PROV	5/3/2004	94-03P US	EXPIRED 5/3/2005
0022(311835)	IBEM 001-US-PSP11	Ipsen	60/569,000	US PROV	5/7/2004	94-03P1 US	EXPIRED 5/7/2005
0022(311835)	IBEM 001-WO-PCT	Ipsen	PCT/US05/014760	WO	4/28/2005	94-03 WO	EXPIRES 4/28/2025

FACTOR VII

Factor VII

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS (Inspiration-JNC Co-Owned)							
90160P(311835)	INSPI.024PR	Inspiration	61/256,802		US PROV	10/30/2009	EXPIRED
90160WO(311835)	INSPI.024WO	Inspiration	PCT/US2010/054581		PCT	10/28/2010	PUBLISHED Nationalized
90160US(311835)	INSPI.024NP	Inspiration	13/459,743		US	4/30/2012	Published
90160EP(311835)	INSPI.024WO	Inspiration	10827499.4		EP	10/28/2010 (PCT date)	Published
90160JP(311835)	TBD	Inspiration	awaiting		JP	10/28/2010 (PCT date)	Pending
RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SALIC ACID CONTENT AND METHODS OF PREPARING SAME (Inspiration JNC co-Owned)							
90207(311835)	INSPI.008NP	Inspiration	12/597,456		US	10/23/2009	PUBLISHED
90207P(311835)	INSPI.008PR	Inspiration	60/914,281		US PROV	4/26/2007	CLOSED
90207WO(311835)	INSPI.008VPC	Inspiration	PCT/US2008/061822		PCT	4/28/2008	EXPIRED
90207AU(311835)	INSPI.008VAU	Inspiration	2008245524		AU	4/28/2008	Pending
90207CA(311835)	INSPI.008VCA	Inspiration	2683423		CA	4/28/2008	Pending
90207EP(311835)	INSPI.008VEP	Inspiration	8747060.5		EP	4/28/2008	Pending
90207JP(311835)	INSPI.008VJP	Inspiration	2010-506563		JP	4/28/2008	PUBLISHED-pending
90207DIVERP(311835)		Inspiration	12170422.5		EP	4/28/2012	Pending-published

Factor VII

EWP Ref No.	Ref No.	Reference Source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
VITAMIN K-DEPENDENT CARBOXYLASE (UNC)							
0026(311835)	90-62	UNC	07/697,427	5470-24	US	5/8/1991	ABANDONED
0026(311835)	90-62	UNC	07/756,250 5,268,275	5470-34	US	9/9/1991	EXPIRED 12/7/2010
0026(311835)	90-62	UNC	PCT/US92/003853	5470-34.1WO	PCT	5/8/1992	EXPIRED
0026(311835)	90-62	UNC	2102702	5470.34.4C A	CA	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 0587742	5470-34.2EP	EP	5/18/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 692325441	5470-34.2DE	DE	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2DK	DK	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2FR	FR	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2GB	GB	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC	92913019.3 587742	5470-34.2ES	SE	5/8/1992	EXPIRES 05/08/2012
0026(311835)	90-62	UNC		5470-34.2AT	AT	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2BE	BE	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2CH	CH	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2ES	ES	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2GR	GR	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2IT	IT	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2LI	LI	5/8/1992	

Factor VII

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
0026(311835)	90-62	UNC		5470-34.2LU	LU	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2MC	MC	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2NL	NL	5/8/1992	
0026(311835)	90-62	UNC		5470-34.2AU	AU	5/8/1992	
CHIMERIC FACTOR VII MOLECULES (UNC)							
0031(311835)	08-0047	UNC	61/220,278	5470-494	US PROV	6/25/2009	EXPIRED
0031(311835)	08-0047	UNC	PCT/US10/039934 WO 10/151736	5470-494WO	PCT	6/25/2010	EXPIRED
0031(311835)	08-0047	UNC		5470-494AU	AU	6/25/2010	N/A
0031(311835)	08-0047	UNC		5470-494BR	BR	6/25/2010	N/A
0031(311835)	08-0047	UNC		5470-494CA	CA	6/25/2010	N/A
0031(311835)	08-0047	UNC		5470-494CN	CN	6/25/2010	N/A
0031(311835)	08-0047	UNC		5470-494EP	EP	6/25/2010	N/A
0031(311835)	08-0047	UNC		5470-494IN	IN	6/25/2010	N/A
0031(311835)	04-0047	UNC		5470-494JP	JP	6/25/2010	N/A
0031(311835)	04-0047	UNC		5470-494RU	RU	6/25/2010	N/A
0031(311835)	04-0047	UNC	12/823,382		US		N/A

Factor VII

EWP Ref No.	Ref No.	Reference source	Application No. / Patent No.	ATTY REF NO.	Country	Filing Date	NOTE
0031(311835)	04-0047	UNC	13/097,609 (co-owned with Inspiration)	5470-4941P	US	4/29/2011	N/A

B6D (Official Form 6D) (12/07)

In re Inspiration Biopharmaceuticals, Inc.
Debtor

Case No. 12-18687

SCHEDULE D - CREDITORS HOLDING SECURED CLAIMS

State the name, mailing address, including zip code, and last four digits of any account number of all entities holding claims secured by property of the debtor as of the date of filing of the petition. The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided if the debtor chooses to do so. List creditors holding all types of secured interests such as judgment liens, garnishments, statutory liens, mortgages, deeds of trust, and other security interests.

List creditors in alphabetical order to the extent practicable. If a minor child is a creditor, the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m). If all secured creditors will not fit on this page, use the continuation sheet provided.

If any entity other than a spouse in a joint case may be jointly liable on a claim, place an "X" in the column labeled "Codebtor", include the entity on the appropriate schedule of creditors, and complete Schedule H - Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be liable on each claim by placing an "H", "W", "J", or "C" in the column labeled "Husband, Wife, Joint, or Community".

If the claim is contingent, place an "X" in the column labeled "Contingent". If the claim is unliquidated, place an "X" in the column labeled "Unliquidated". If the claim is disputed, place an "X" in the column labeled "Disputed". (You may need to place an "X" in more than one of these three columns.)

Total the columns labeled "Amount of Claim Without Deducting Value of Collateral" and "Unsecured Portion, if Any" in the boxes labeled "Total(s)" on the last sheet of the completed schedule. Report the total from the column labeled "Amount of Claim" also on the Summary of Schedules and, if the debtor is an individual with primarily consumer debts, report the total from the column labeled "Unsecured Portion" on the Statistical Summary of Certain Liabilities and Related Data.

Check this box if debtor has no creditors holding secured claims to report on this Schedule D.

CREDITOR'S NAME AND MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions above.)	C O D E B T O R H W J C	Husband, Wife, Joint, or Community	DATE CLAIM WAS INCURRED, NATURE OF LIEN, AND DESCRIPTION AND VALUE OF PROPERTY SUBJECT TO LIEN	C O N T I N G E N T	U N L I Q U I D A T E D	D I S P U T E D	AMOUNT OF CLAIM WITHOUT DEDUCTING VALUE OF COLLATERAL	UNSECURED PORTION, IF ANY
Account No.								
Edwards Wildman Palmer LLC PO Box 416395 Boston, MA 02241-6395	-					X	202,521.65	Unknown
Account No.								
Ipsen Pharma S.A.S. 65, quai Georges Gorse 92100 Boulogne Billancourt - France Attention: Willy Mathot	-		Five Long-term Convertible Promissory Notes dated 1/22/10, 11/19/10, 9/29/11, 11/23/11 and 4/12/12			X	203,101,289.00	Unknown
Account No.								
Account No.								
Subtotal (Total of this page)							203,303,810.65	0.00
Total (Report on Summary of Schedules)							203,303,810.65	0.00

0 continuation sheets attached

In re Inspiration Biopharmaceuticals, Inc.

Debtor

Case No. 12-18687

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS

A complete list of claims entitled to priority, listed separately by type of priority, is to be set forth on the sheets provided. Only holders of unsecured claims entitled to priority should be listed in this schedule. In the boxes provided on the attached sheets, state the name, mailing address, including zip code, and last four digits of the account number, if any, of all entities holding priority claims against the debtor or the property of the debtor, as of the date of the filing of the petition. Use a separate continuation sheet for each type of priority and label each with the type of priority.

The complete account number of any account the debtor has with the creditor is useful to the trustee and the creditor and may be provided if the debtor chooses to do so. If a minor child is a creditor, state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See, 11 U.S.C. §112 and Fed. R. Bankr. P. 1007(m).

If any entity other than a spouse in a joint case may be jointly liable on a claim, place an "X" in the column labeled "Codebtor," include the entity on the appropriate schedule of creditors, and complete Schedule H-Codebtors. If a joint petition is filed, state whether the husband, wife, both of them, or the marital community may be liable on each claim by placing an "H," "W," "J," or "C" in the column labeled "Husband, Wife, Joint, or Community." If the claim is contingent, place an "X" in the column labeled "Contingent." If the claim is unliquidated, place an "X" in the column labeled "Unliquidated." If the claim is disputed, place an "X" in the column labeled "Disputed." (You may need to place an "X" in more than one of these three columns.)

Report the total of claims listed on each sheet in the box labeled "Subtotals" on each sheet. Report the total of all claims listed on this Schedule E in the box labeled "Total" on the last sheet of the completed schedule. Report this total also on the Summary of Schedules.

Report the total of amounts entitled to priority listed on each sheet in the box labeled "Subtotals" on each sheet. Report the total of all amounts entitled to priority listed on this Schedule E in the box labeled "Totals" on the last sheet of the completed schedule. Individual debtors with primarily consumer debts report this total also on the Statistical Summary of Certain Liabilities and Related Data.

Report the total of amounts not entitled to priority listed on each sheet in the box labeled "Subtotals" on each sheet. Report the total of all amounts not entitled to priority listed on this Schedule E in the box labeled "Totals" on the last sheet of the completed schedule. Individual debtors with primarily consumer debts report this total also on the Statistical Summary of Certain Liabilities and Related Data.

Check this box if debtor has no creditors holding unsecured priority claims to report on this Schedule E.

TYPES OF PRIORITY CLAIMS (Check the appropriate box(es) below if claims in that category are listed on the attached sheets)

Domestic support obligations

Claims for domestic support that are owed to or recoverable by a spouse, former spouse, or child of the debtor, or the parent, legal guardian, or responsible relative of such a child, or a governmental unit to whom such a domestic support claim has been assigned to the extent provided in 11 U.S.C. § 507(a)(1).

Extensions of credit in an involuntary case

Claims arising in the ordinary course of the debtor's business or financial affairs after the commencement of the case but before the earlier of the appointment of a trustee or the order for relief. 11 U.S.C. § 507(a)(3).

Wages, salaries, and commissions

Wages, salaries, and commissions, including vacation, severance, and sick leave pay owing to employees and commissions owing to qualifying independent sales representatives up to \$11,725* per person earned within 180 days immediately preceding the filing of the original petition, or the cessation of business, whichever occurred first, to the extent provided in 11 U.S.C. § 507(a)(4).

Contributions to employee benefit plans

Money owed to employee benefit plans for services rendered within 180 days immediately preceding the filing of the original petition, or the cessation of business, whichever occurred first, to the extent provided in 11 U.S.C. § 507(a)(5).

Certain farmers and fishermen

Claims of certain farmers and fishermen, up to \$5,775* per farmer or fisherman, against the debtor, as provided in 11 U.S.C. § 507(a)(6).

Deposits by individuals

Claims of individuals up to \$2,600* for deposits for the purchase, lease, or rental of property or services for personal, family, or household use, that were not delivered or provided. 11 U.S.C. § 507(a)(7).

Taxes and certain other debts owed to governmental units

Taxes, customs duties, and penalties owing to federal, state, and local governmental units as set forth in 11 U.S.C. § 507(a)(8).

Commitments to maintain the capital of an insured depository institution

Claims based on commitments to the FDIC, RTC, Director of the Office of Thrift Supervision, Comptroller of the Currency, or Board of Governors of the Federal Reserve System, or their predecessors or successors, to maintain the capital of an insured depository institution. 11 U.S.C. § 507(a)(9).

Claims for death or personal injury while debtor was intoxicated

Claims for death or personal injury resulting from the operation of a motor vehicle or vessel while the debtor was intoxicated from using alcohol, a drug, or another substance. 11 U.S.C. § 507(a)(10).

* Amount subject to adjustment on 4/01/13, and every three years thereafter with respect to cases commenced on or after the date of adjustment.

B6E (Official Form 6E) (4/10) - Cont.

In re Inspiration Biopharmaceuticals, Inc.
Debtor

Case No. 12-18687

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS
(Continuation Sheet)

Wages, salaries, and commissions

TYPE OF PRIORITY

CREDITOR'S NAME, AND MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions.)	C O D E B O R	H W J C	Husband, Wife, Joint, or Community DATE CLAIM WAS INCURRED AND CONSIDERATION FOR CLAIM	C O N T I N G E N T	U N L I Q U I D A T E D	D I S P U T E D	AMOUNT OF CLAIM	AMOUNT NOT ENTITLED TO PRIORITY, IF ANY
								AMOUNT ENTITLED TO PRIORITY
Account No. Andrew Elnatan 192 Sydney Street Unit D Boston, MA 02122		-					1,598.56	0.00 1,598.56
Account No. Christopher Marston 31616 Virginia Beach Laguna Beach, CA 92651		-					11,725.00	0.00 11,725.00
Account No. David Andrews 13 Bexley Drive Hudson, MA 01749		-					8,703.58	0.00 8,703.58
Account No. John Butler 85 Mosher Lane Marlborough, MA 01752		-					11,725.00	0.00 11,725.00
Account No. Karen Tubridy 41 Oak Cliff Road Newton, MA 02460		-					8,480.75	0.00 8,480.75
Subtotal								0.00
(Total of this page)							42,232.89	42,232.89

Sheet 1 of 4 continuation sheets attached to
Schedule of Creditors Holding Unsecured Priority Claims

B6E (Official Form 6E) (4/10) - Cont.

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS
(Continuation Sheet)

Wages, salaries, and commissions

TYPE OF PRIORITY

CREDITOR'S NAME, AND MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions.)	C O D E D E B T O R	H U S B A N D, W I F E, J O I N T, O R C O M M U N I T Y	D A T E C L A I M W A S I N C U R R E D A N D C O N S I D E R A T I O N F O R C L A I M	C O N T I N G E N T	U N L I Q U I D A T E D	D I S P U T E D	A M O U N T O F C L A I M	AMOUNT NOT ENTITLED TO PRIORITY, IF ANY
								A M O U N T E N T I T L E D T O P R I O R I T Y
Account No. Kathleen Seaber 1000 Kenion Road Hillsborough, NC 27278	-						10,387.53	0.00 10,387.53
Account No. Kerry Biron 235 Union Avenue Pascoag, RI 02859	-						11,725.00	0.00 11,725.00
Account No. Lorrie M. Ferraro 50 Rogers St North Billerica, MA 01862	-						8,612.58	0.00 8,612.58
Account No. Mark DeRosch 18-303 Mountain Laurels Dr. Nashua, NH 03062	-						7,210.82	0.00 7,210.82
Account No. Melissa Gelormini 410 Salem Street #904 Wakefield, MA 01880	-						1,416.39	0.00 1,416.39
Subtotal								0.00
(Total of this page)							39,352.32	39,352.32

Sheet 2 of 4 continuation sheets attached to
Schedule of Creditors Holding Unsecured Priority Claims

B6E (Official Form 6E) (4/10) - Cont.

In re Inspiration Biopharmaceuticals, Inc.

Case No. 12-18687

Debtor

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS
(Continuation Sheet)

Wages, salaries, and commissions

TYPE OF PRIORITY

CREDITOR'S NAME, AND MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions.)	C O D E B T O R	H W J C	Husband, Wife, Joint, or Community DATE CLAIM WAS INCURRED AND CONSIDERATION FOR CLAIM	C O N T I N G E N T	U N L I Q U I D A T E D	D I S P U T E D	AMOUNT OF CLAIM	AMOUNT NOT ENTITLED TO PRIORITY, IF ANY
								AMOUNT ENTITLED TO PRIORITY
Account No. Michael J. Keaveny 1330 Boylston Street Apt 916 Boston, MA 02215		-					6,623.94	0.00 6,623.94
Account No. Michel Dahan 51 Trowbridge St., Apt 3 Cambridge, MA 02140		-					11,725.00	0.00 11,725.00
Account No. Neil Schauer 30 Mill Pond Circle Milford, MA 01757		-					8,145.17	0.00 8,145.17
Account No. Nicole R. Hadas 20 Pilgrim Drive Winchester, MA 01890		-					11,725.00	0.00 11,725.00
Account No. Robert J. Corcoran 3 Holworthy Way Beverly, MA 01915		-					9,253.49	0.00 9,253.49
Subtotal (Total of this page)							47,472.60	0.00 47,472.60

Sheet 3 of 4 continuation sheets attached to
Schedule of Creditors Holding Unsecured Priority Claims

B6E (Official Form 6E) (4/10) - Cont.

In re Inspiration Biopharmaceuticals, Inc.
Debtor

Case No. 12-18687

SCHEDULE E - CREDITORS HOLDING UNSECURED PRIORITY CLAIMS
(Continuation Sheet)

Wages, salaries, and commissions

TYPE OF PRIORITY

CREDITOR'S NAME, AND MAILING ADDRESS INCLUDING ZIP CODE, AND ACCOUNT NUMBER (See instructions.)	C O D E F O R H W J C	Husband, Wife, Joint, or Community	D A T E C L A I M W A S I N C U R R E D A N D C O N S I D E R A T I O N F O R C L A I M	C O N T I N G E N T	U N L I Q U I D A T E D	D I S P U T E D	AMOUNT OF CLAIM	AMOUNT NOT ENTITLED TO PRIORITY, IF ANY
								AMOUNT ENTITLED TO PRIORITY
Account No. Salvatore Firicano 33 Appleton Street Melrose, MA 02176	-						6,910.26	0.00 6,910.26
Account No. Traci Tuttle 16 Walker Lane Fremont, NH 03044	-						1,192.58	0.00 1,192.58
Account No. Tung Koh 12 Flora Springs Irvine, CA 92602	-						11,725.00	0.00 11,725.00
Account No.								
Account No.								
Account No.								
Subtotal (Total of this page)							19,827.84	0.00 19,827.84
Total (Report on Summary of Schedules)							148,885.65	0.00 148,885.65

Sheet 4 of 4 continuation sheets attached to
Schedule of Creditors Holding Unsecured Priority Claims